Pegenzileukin

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NamePegenzileukin
Drug Alias NameTHOR-707SAR-444245IBI-127
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor subunit gamma stimulantsInterleukin-2 receptor beta chain agonists
TargetsInterleukin-2 receptor subunit gammaInterleukin-2 receptor beta chain
Therapy Area/IndicationsEsophageal adenocarcinomaNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSynthorx Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesSynthorx IncThe University Of Texas MD Anderson Cancer CenterSanofi-Aventis Recherche & Developpement +[5] 
Active IndicationsEsophageal adenocarcinomaStomach NeoplasmsColorectal Neoplasms +[6] 
Inactive IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungSkin Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A